WeBD.Tokyo - We grow Japan for your CDMO&Biotech

You land in Tokyo and hit a hard truth: LinkedIn isn’t how deals get done here, and English opens fewer doors than you expect. Japan rewards trusted local presence, patient follow-up, and native-language execution. That’s exactly where WeBD.Tokyo comes in.

WeBD.Tokyo is a hands-on market-entry partner for European CDMOs and biotech companies. We blend business development, regulatory/quality know-how, and on-the-ground representation to convert interest into signed work—and trials into commercial paths. From the signature, we continue to support the co-development

For CDMOs
• Map and prioritize Japanese accounts, run multilingual outreach, secure RFQs, and manage technical/QMS dialogues to audit readiness.
• Position differentiated technologies to the right buyer groups in pharma and specialty innovators.
• Build repeatable pipelines via Representation-as-a-Service (monthly retainer), or spin up a JV/local entity when scale justifies it. (MAH hosting options available.)

For Biotech
• Structure out-licensing, co-development, and option deals; prepare JP-first or JP-inclusive partnering narratives and meeting packs.
• Identify and engage clinical partners and KOLs; align trial assumptions with JP practice and payer reality.
• Fundraising support: introductions to strategic pharma investors and CVCs, family offices, and non-dilutive opportunities; coaching on JP materials and diligence.

Go-to-market execution
• Meeting generation at BioJapan, CPHI Japan, Interphex, and targeted roadshows.
• Japanese-language PR and presence building (media notes, event speaking, buyer follow-ups).
• Term-sheet support with cultural translation, then operational hand-off to quality/regulatory teams (GQP/GVP/SOP frameworks available).

Our promise: pragmatic, bilingual execution (not just English and Japanese, but also Science and Business) that respects Japanese process while protecting your speed and margins—turning Japan from a black box into a reliable growth lane.

And why trust us? I’ve worked inside Pfizer Japan and spent a decade at a CDMOs in CH. I use that buyer’s-side perspective—and local network—to help you open the market.